Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (11-20 of 631) with videos related to

Pageof 64
Sort By:
Hepatobiliary Surgery and Nutrition|February 12, 2021
Hepatitis C-committing the world to an eradication of the infectionJohannes Wiegand, Thomas Berg
Journal of Hepatology|June 23, 2022
Thriving in turbulent times: EASL reflects on 2021, looking to 2022 and beyondThomas Berg, Aleksander Krag
Journal of Hepatology|February 8, 2018
Reply to: "Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients"Thomas Berg, Jörg Petersen,
Hepatobiliary Surgery and Nutrition|May 1, 2023
Clinical practice guidelines for acute-on-chronic liver failure: are we ready for reaching global consensus?Cornelius Engelmann, Thomas Berg
Journal of Hepatology|May 6, 2021
The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapyThomas Berg, Pietro Lampertico
Pharmazie in Unserer Zeit|January 4, 2011
[Diagnosis and clinical features of infection with hepatitis A and hepatitis E viruses. Transmission through drinking water and foodstuffs]Julia Benckert, Thomas Berg
Hepatology (Baltimore, Md.)|January 31, 2018
Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis BPietro Lampertico, Thomas Berg
Gastroenterology|June 3, 2009
Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirinMichael Biermer, Thomas Berg
Deutsches Arzteblatt International|March 2, 2013
The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosisJohannes Wiegand, Thomas Berg
Journal of Hepatology|June 15, 2023
The future of hepatology - "The best way to predict the future is to create it"Thomas Berg, Aleksander Krag
Pageof 64

Showing results (11-20 of 631) with videos related to

Sort By:
Pageof 64
Hepatobiliary Surgery and Nutrition|February 12, 2021
Hepatitis C-committing the world to an eradication of the infectionJohannes Wiegand, Thomas Berg
Journal of Hepatology|June 23, 2022
Thriving in turbulent times: EASL reflects on 2021, looking to 2022 and beyondThomas Berg, Aleksander Krag
Journal of Hepatology|February 8, 2018
Reply to: "Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients"Thomas Berg, Jörg Petersen,
Hepatobiliary Surgery and Nutrition|May 1, 2023
Clinical practice guidelines for acute-on-chronic liver failure: are we ready for reaching global consensus?Cornelius Engelmann, Thomas Berg
Journal of Hepatology|May 6, 2021
The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapyThomas Berg, Pietro Lampertico
Pharmazie in Unserer Zeit|January 4, 2011
[Diagnosis and clinical features of infection with hepatitis A and hepatitis E viruses. Transmission through drinking water and foodstuffs]Julia Benckert, Thomas Berg
Hepatology (Baltimore, Md.)|January 31, 2018
Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis BPietro Lampertico, Thomas Berg
Gastroenterology|June 3, 2009
Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirinMichael Biermer, Thomas Berg
Deutsches Arzteblatt International|March 2, 2013
The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosisJohannes Wiegand, Thomas Berg
Journal of Hepatology|June 15, 2023
The future of hepatology - "The best way to predict the future is to create it"Thomas Berg, Aleksander Krag
Pageof 64